| Authors: |
Clegg LE; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gaithersburg, MD lindsay.clegg1@astrazeneca.com., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Penland RC; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA., Tang W; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gaithersburg, MD., Boulton DW; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gaithersburg, MD., Bachina S; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA., Fox RD; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA., Fenici P; AstraZeneca, Cambridge, U.K., Thuresson M; Statisticon AB, Uppsala, Sweden., Mentz RJ; Duke University and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Hernandez AF; Duke University and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Holman RR; Diabetes Trials Unit, University of Oxford, Oxford, U.K. |
